Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Biotech
Biohaven trashes troriluzole in OCD after ph. 3 fail
This is the second OCD trial the asset has failed and the latest in a string of clinical turbulence for the drug.
Darren Incorvaia
Aug 12, 2025 2:06pm
Cancer vaccine's 'narrow' fail won't stop IO heading to FDA
Aug 11, 2025 9:48am
Vertex drops asset in acute pain after phase 2 fail
Aug 4, 2025 5:34pm
Spine BioPharma misses primary endpoint in back pain phase 3
Aug 1, 2025 10:24am
Nuvectis axes ovarian cancer program after seeing phase 1b data
Jul 31, 2025 9:15am
Vyne's BET inhibitor fails phase 2 vitiligo trial, sinking stock
Jul 30, 2025 9:35am
